N-[1-[4-(4-acetamidophenyl)phenyl]-2-morpholin-4-ylethyl]-2-(6,7-dimethyl-3-oxo-1,4-benzoxazin-4-yl)-N-methylacetamide | 1003876-62-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[1-[4-(4-acetamidophenyl)phenyl]-2-morpholin-4-ylethyl]-2-(6,7-dimethyl-3-oxo-1,4-benzoxazin-4-yl)-N-methylacetamide
• CAS: 1003876-62-7
• 化学式: C₃₃H₃₈N₄O₅
• 分子量: 570.689
• InChiKey: BEKQKLIWZQJREN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  42
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  91.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  C₂₅H₃₀BrN₃O₄ 、 4-乙酰胺基苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.1h， 生成 N-[1-[4-(4-acetamidophenyl)phenyl]-2-morpholin-4-ylethyl]-2-(6,7-dimethyl-3-oxo-1,4-benzoxazin-4-yl)-N-methylacetamide
  参考文献：
  名称：

  Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles

  摘要：

  Lead compound 1 was successfully redesigned to provide compounds with improved pharmacokinetic profiles for this series of human urotensin-II antagonists. Replacement of the 2-pyrrolidinylmethyl-3-phenyl-piperidine core of 1 with a substituted N-methyl-2-(1-pyrrolidinyl) ethanamine core as in compound 7 resulted in compounds with improved oral bioavailability in rats. The relationship between stereochemistry and selectivity for hUT over the kappa-opioid receptor was also explored. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.058

文献信息

• MORPHOLINYL AND PYRROLIDINYL ANALOGS
  申请人：Goodman Krista B.

  公开号：US20080021023A1

  公开（公告）日：2008-01-24

  The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.

  本发明涉及吗吗啉基和吡咯啉基类似物，含有它们的药物组合物，以及它们作为尿苷II拮抗剂的用途。
• US7432258B2
  申请人：——

  公开号：US7432258B2

  公开（公告）日：2008-10-07
• US7749998B2
  申请人：——

  公开号：US7749998B2

  公开（公告）日：2010-07-06
• [EN] MORPHOLINYL AND PYRROLIDINYL ANALOGS<br/>[FR] ANALOGUES DE MORPHOLINYLE ET DE PYRROLIDINYLE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2008011551A1

  公开（公告）日：2008-01-24

  [EN] The present invention relates to morpholinyl, and pyrrolidinyl analogs, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
  [FR] La présente invention concerne des analogues de morpholinyle et de pyrrolidinyle, des compositions pharmaceutiques les contenant et leur utilisation comme antagonistes de l'urotensine II.
• Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles
  作者：John J. McAtee、Jason W. Dodson、Sarah E. Dowdell、Karl Erhard、Gerald R. Girard、Krista B. Goodman、Mark A. Hilfiker、Jian Jin、Clark A. Sehon、Deyou Sha、Dongchuan Shi、Feng Wang、Gren Z. Wang、Ning Wang、Yonghui Wang、Andrew Q. Viet、Catherine C.K. Yuan、Daohua Zhang、Nambi V. Aiyar、David J. Behm、Luz H. Carballo、Christopher A. Evans、Harvey E. Fries、Rakesh Nagilla、Theresa J. Roethke、Xiaoping Xu、Stephen A. Douglas、Michael J. Neeb

  DOI：10.1016/j.bmcl.2008.05.058

  日期：2008.7

  Lead compound 1 was successfully redesigned to provide compounds with improved pharmacokinetic profiles for this series of human urotensin-II antagonists. Replacement of the 2-pyrrolidinylmethyl-3-phenyl-piperidine core of 1 with a substituted N-methyl-2-(1-pyrrolidinyl) ethanamine core as in compound 7 resulted in compounds with improved oral bioavailability in rats. The relationship between stereochemistry and selectivity for hUT over the kappa-opioid receptor was also explored. (C) 2008 Elsevier Ltd. All rights reserved.